News & Updates

Treatment with bimekizumab (BKZ) for over 3 years does not result in the occurrence of new adverse events (AEs), demonstrating its positive safety profile in patients with moderate-to-severe plaque psoriasis, as shown by a pooled analysis of five phase III/IIIb trials presented at EADV 2023.

Treatment with risankizumab (RZB) results in significantly lower absolute Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores at week 52 in bio-naïve psoriasis patients compared with other biologic therapies, according to the results of a 2-year interim analysis from the German cohort of the VALUE study, presented at EADV 2023.

A population-based study suggests that the incidence of periodontitis co-occurs with various other diabetes-related complications, underpinning the importance of oral health checks in diabetes management.

Twice-daily application of the botanical coacillium 22.25% cutaneous solution leads to significant hair growth in children and adolescents with moderate-to-severe alopecia areata (AA), with the improvement in hair loss sustained through months after treatment discontinuation, according to data from the phase II/III RAAINBOW trial.

The monovalent mRNA vaccine helped stave off severe COVID-19 outcomes in children aged 1 to 4 years during the Omicron wave, as shown in a study from Singapore.

Ischaemic stroke (IS) patients with consistently controlled blood pressure (BP) and who regularly take antihypertensive medications following discharge have lower risks of death and vascular events, reports a recent study.